Association Between Triglycerides Glucose Ratio With HOMA -IR as Indicators of Insulin Resistance in Obese Adults

April 6, 2024 updated by: Ayat Esmat Mohamed Kotb, Assiut University
The aim of the present study was to investigate the correlation between the triglyceride/glucose index (TyG index) and homeostasic model assessment of insulin resistance (HOMA-IR) to predict insulin resistance (IR) in obese adults

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Obesity is a chronic disease that has an increasing prevalence in both developed and developing countries and affects adults and children[1] Obesity is an important risk factor for the development of some chronic diseases such as insulin resistance, hypertension, and type 2 diabetes [2]

. Insulin sensitivity is inversely related to body mass index and body fat. Insulin resistance can be defined as impairment of the normal biological response to both endogenous and exogenous insulin. One of the primary defects underlying the development of type 2 diabetes is thought to be insulin resistance. So, it is present in 85% of these patients with Type 2 DM. It is also related to the pathogenesis of many illnesses which includes coronary heart disease, and hypertension[3] Early detection of insulin resistance (IR) is important to prevent the development of cardiometabolic diseases such as Type 2 Diabetes Mellitus, metabolic syndrome, and coronary heart disease. The Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index, which has high sensitivity and specificity, has been shown to be more useful in estimating the risk of insulin resistance, instead of more invasive, complex, and expensive direct tests such as pancreatic suppression test and hyperinsulinemic-euglycemic glucose clamp technique [4] HOMA-IR is an approved method for evaluating insulin resistance using fasting glucose and insulin levels and is widely used in clinical practice [5].

Triglyceride glucose (TyG) index is a novel marker, which has been demonstrated to have a high sensitivity and specificity in identifying insulin resistance [6].

Recently, the use of the triglyceride glucose (TyG) index, a product of fasting glucose and triglyceride are more easily accessible assessment tools both at the outpatient clinics and at the community level, and are low cost [7].

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Any obese adult (18 years or older) with BMI greater than or equal 30 of both sexes admitted to assiut unversity hospitals and clinics

Description

Inclusion Criteria:

  • Any obese adult (18 years or older) with BMI greater than or equal 30 of both sexes admitted to assiut unversity hospitals and clinics

Exclusion Criteria:

  • Cases <18 years old
  • Cases with BMI < 30
  • Adult with endocrine abnormatilies under treatment for DM ,hypertension , dyslipidemia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association between triglycerides glucose ratio with HOMA -IR as indicators of insulin resistance in obese adults
Time Frame: Baseline
The study is to investigate the usability of the Ty-G index as an indicator of insulin resistance in obese adults according to its correlation with HOMA-IR
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2024

Primary Completion (Estimated)

April 1, 2025

Study Completion (Estimated)

May 1, 2025

Study Registration Dates

First Submitted

April 6, 2024

First Submitted That Met QC Criteria

April 6, 2024

First Posted (Actual)

April 11, 2024

Study Record Updates

Last Update Posted (Actual)

April 11, 2024

Last Update Submitted That Met QC Criteria

April 6, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Insulin resistance

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Insulin Resistance

Clinical Trials on HOMA IR

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe